Allogene Approaches Key Data Release for ALPHA3 Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy ALLO?
"Allogene is approaching a pivotal inflection point, with the first interim data of cema-cel's ALPHA3 trial just weeks away," said David Chang, president, CEO and co-founder of Allogene. "We designed ALPHA3 to answer a bold question: can early, MRD-guided allogeneic CAR T prevent relapse in LBCL? We believe that this trial will answer that question and has the potential to mark one of the most significant advances in the field in decades. Importantly, through ALPHA3 we are working to demonstrate that allogeneic CAR T can move beyond academic settings and be delivered at biologic-like scale. Beyond oncology, ALLO-329 demonstrates how our Dagger(R) technology may redefine the delivery of CAR T in autoimmune disease. Supported by a cash runway into 2028, we are focused on disciplined execution and delivering transformative data across our portfolio."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALLO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALLO
Wall Street analysts forecast ALLO stock price to rise
11 Analyst Rating
10 Buy
0 Hold
1 Sell
Strong Buy
Current: 2.260
Low
5.00
Averages
8.50
High
14.00
Current: 2.260
Low
5.00
Averages
8.50
High
14.00
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
El Pollo Loco Surges After Strong Q4 Earnings Beat Estimates
- Strong Earnings Report: El Pollo Loco reported Q4 earnings of $0.25 per share, surpassing analyst expectations of $0.20, indicating robust profitability that boosts investor confidence.
- Sales Exceed Expectations: The company achieved quarterly sales of $123.515 million, exceeding the analyst consensus of $122.783 million, demonstrating sustained strong market demand that drives overall performance.
- Stock Rating Upgrade: Benchmark upgraded El Pollo Loco's stock from Hold to Buy, reflecting a positive outlook on the company's future growth potential, which may attract more investor interest.
- Significant Stock Price Increase: Following the earnings report, El Pollo Loco's stock surged 17.6% to $12.79, indicating a strong market reaction to its financial performance and further solidifying its competitive position in the fast-food industry.
See More
Allogene Therapeutics Q4 2025 Earnings Call Insights
- Clinical Milestones: CEO David Chang emphasized that 2026 will be a 'defining year' for Allogene Therapeutics, focusing on clinical progress for the ALPHA3 and ALLO-329 programs, with key data expected in April and June, which will enhance the company's market position in cell therapy.
- Financial Health: As of December 31, 2025, the company reported $258.3 million in cash and equivalents, with management guiding for operating cash expenses of approximately $150 million in 2026, extending the cash runway into Q1 2028, ensuring sufficient funding for critical clinical trials.
- R&D Expenditures: The fourth quarter saw R&D expenses of $28.6 million, including $2.5 million in noncash stock compensation, with a net loss of $38.8 million, indicating ongoing investment in clinical trials while reflecting financial pressures in a competitive market.
- Market Positioning: Management remains optimistic about the clinical data from ALPHA3 and ALLO-329, emphasizing the relationship between MRD clearance rates and clinical outcomes, with upcoming data releases aimed at validating their treatment approaches and enhancing competitive positioning in the market.
See More
Allogene (ALLO) Q4 2025 Earnings Call Transcript
See More
Allogene Therapeutics Q4 Earnings Beat Expectations
- Strong Earnings Performance: Allogene Therapeutics reported a Q4 GAAP EPS of -$0.17, beating expectations by $0.05, indicating improvements in financial management that may boost investor confidence.
- Robust Cash Reserves: As of December 31, 2025, the company had $258.3 million in cash, cash equivalents, and investments, ensuring operational stability for the coming years and supporting its R&D and market expansion plans.
- Extended Cash Runway: Based on its current cash reserves, the company projects its cash runway extending into Q1 2028, providing ample funding for long-term strategic initiatives, including new product development and market outreach.
- Positive Market Response: Allogene Therapeutics' presentation at Citi's 2026 Virtual Oncology Leadership Summit garnered attention, with the market showing optimism about its future prospects, potentially attracting more investor interest and participation.
See More
Allogene Therapeutics to Announce Q4 Earnings on March 12
- Earnings Announcement: Allogene Therapeutics is set to release its Q4 earnings report on March 12 after market close, with a consensus EPS estimate of -$0.22, indicating ongoing challenges in profitability.
- Historical Performance Review: Over the past year, Allogene has beaten EPS estimates 50% of the time and revenue estimates 50% of the time, reflecting a degree of stability amid market fluctuations.
- Recent Estimate Adjustments: In the last three months, there has been one upward revision and no downward revisions to EPS estimates, suggesting an increased confidence among analysts regarding the company's future performance, which may influence investor decisions.
- Increased Market Attention: Allogene recently presented at Citi's 2026 Virtual Oncology Leadership Summit, highlighting the company's ongoing focus and strategic positioning in the oncology treatment space, which could attract more investor interest.
See More
Allogene Therapeutics Schedules Q4 2025 Earnings Call
- Earnings Release Schedule: Allogene Therapeutics will report its Q4 and full-year 2025 financial results on March 12, 2026, after market close, highlighting advancements in cancer and autoimmune disease treatments.
- Live Webcast Conference: Following the earnings release, the company will host a live audio webcast at 2:00 p.m. PT/5:00 p.m. ET, allowing investors to stay updated and ask questions.
- Conference Call Registration: Investors wishing to ask questions during the call can register via the provided link, receiving a personal PIN for access, enhancing engagement opportunities.
- Cautionary Note on Forward-Looking Statements: The press release includes forward-looking statements that outline risks and uncertainties related to Allogene's ability to develop allogeneic CAR T products, urging investors to consider these factors in their assessments.
See More
El Pollo Loco Surges After Strong Q4 Earnings Beat Estimates
- Strong Earnings Report: El Pollo Loco reported Q4 earnings of $0.25 per share, surpassing analyst expectations of $0.20, indicating robust profitability that boosts investor confidence.
- Sales Exceed Expectations: The company achieved quarterly sales of $123.515 million, exceeding the analyst consensus of $122.783 million, demonstrating sustained strong market demand that drives overall performance.
- Stock Rating Upgrade: Benchmark upgraded El Pollo Loco's stock from Hold to Buy, reflecting a positive outlook on the company's future growth potential, which may attract more investor interest.
- Significant Stock Price Increase: Following the earnings report, El Pollo Loco's stock surged 17.6% to $12.79, indicating a strong market reaction to its financial performance and further solidifying its competitive position in the fast-food industry.
See More
Allogene Therapeutics Q4 2025 Earnings Call Insights
- Clinical Milestones: CEO David Chang emphasized that 2026 will be a 'defining year' for Allogene Therapeutics, focusing on clinical progress for the ALPHA3 and ALLO-329 programs, with key data expected in April and June, which will enhance the company's market position in cell therapy.
- Financial Health: As of December 31, 2025, the company reported $258.3 million in cash and equivalents, with management guiding for operating cash expenses of approximately $150 million in 2026, extending the cash runway into Q1 2028, ensuring sufficient funding for critical clinical trials.
- R&D Expenditures: The fourth quarter saw R&D expenses of $28.6 million, including $2.5 million in noncash stock compensation, with a net loss of $38.8 million, indicating ongoing investment in clinical trials while reflecting financial pressures in a competitive market.
- Market Positioning: Management remains optimistic about the clinical data from ALPHA3 and ALLO-329, emphasizing the relationship between MRD clearance rates and clinical outcomes, with upcoming data releases aimed at validating their treatment approaches and enhancing competitive positioning in the market.
See More
Allogene (ALLO) Q4 2025 Earnings Call Transcript
See More
Allogene Therapeutics Q4 Earnings Beat Expectations
- Strong Earnings Performance: Allogene Therapeutics reported a Q4 GAAP EPS of -$0.17, beating expectations by $0.05, indicating improvements in financial management that may boost investor confidence.
- Robust Cash Reserves: As of December 31, 2025, the company had $258.3 million in cash, cash equivalents, and investments, ensuring operational stability for the coming years and supporting its R&D and market expansion plans.
- Extended Cash Runway: Based on its current cash reserves, the company projects its cash runway extending into Q1 2028, providing ample funding for long-term strategic initiatives, including new product development and market outreach.
- Positive Market Response: Allogene Therapeutics' presentation at Citi's 2026 Virtual Oncology Leadership Summit garnered attention, with the market showing optimism about its future prospects, potentially attracting more investor interest and participation.
See More
Allogene Therapeutics to Announce Q4 Earnings on March 12
- Earnings Announcement: Allogene Therapeutics is set to release its Q4 earnings report on March 12 after market close, with a consensus EPS estimate of -$0.22, indicating ongoing challenges in profitability.
- Historical Performance Review: Over the past year, Allogene has beaten EPS estimates 50% of the time and revenue estimates 50% of the time, reflecting a degree of stability amid market fluctuations.
- Recent Estimate Adjustments: In the last three months, there has been one upward revision and no downward revisions to EPS estimates, suggesting an increased confidence among analysts regarding the company's future performance, which may influence investor decisions.
- Increased Market Attention: Allogene recently presented at Citi's 2026 Virtual Oncology Leadership Summit, highlighting the company's ongoing focus and strategic positioning in the oncology treatment space, which could attract more investor interest.
See More
Allogene Therapeutics Schedules Q4 2025 Earnings Call
- Earnings Release Schedule: Allogene Therapeutics will report its Q4 and full-year 2025 financial results on March 12, 2026, after market close, highlighting advancements in cancer and autoimmune disease treatments.
- Live Webcast Conference: Following the earnings release, the company will host a live audio webcast at 2:00 p.m. PT/5:00 p.m. ET, allowing investors to stay updated and ask questions.
- Conference Call Registration: Investors wishing to ask questions during the call can register via the provided link, receiving a personal PIN for access, enhancing engagement opportunities.
- Cautionary Note on Forward-Looking Statements: The press release includes forward-looking statements that outline risks and uncertainties related to Allogene's ability to develop allogeneic CAR T products, urging investors to consider these factors in their assessments.
See More
